Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13912658 | 0.81 | SLC6A2 (0.37) | SLC6A4SLC6A2 | |
| SCHEMBL349206 | 0.79 | OPRM1 (0.44) | SLC6A4SLC6A2SLC6A3PDE4APDE4B | |
| SCHEMBL4092897 | 0.75 | SLC6A4 (0.34) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL13902235 | 0.72 | SLC6A2 (0.40) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL7468364 | 0.70 | OPRL1 (0.41) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4446561 | 0.69 | OPRM1 (0.37) | — | |
| SCHEMBL1557061 | 0.68 | OPRM1 (0.43) | PDE4B | |
| SCHEMBL14258204 | 0.67 | KMT2A (0.33) | — | |
| SCHEMBL4100469 | 0.67 | HSD11B1 (0.46) | — | |
| SCHEMBL8106592 | 0.67 | ALDH1A1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1995243-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | HSD11B1, HSD11B2, HSD17B1 | SLC6A4 704/4885SLC6A2 1397/4885SLC6A3 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.